First Patient Dosed in Hong Kong Clinical Trial of PLT012 for Liver Cancer Expansion
“Dosing the first patient in Hong Kong represents an important milestone for the PLT012 program and for Pilatus as we continue expanding the global clinical development of our lead program,” said Raven Lin, Ph.D., Chief Executive Officer and Co-Founder, Pilatus Biosciences. “By collecting clinical and biomarker data from patients with HCC, we aim to better understand PLT012’s broader anti-tumor activity, inform its next stage of development supported by FDA Fast Track Designation, and further explore mechanisms associated with response to immunotherapy in HCC. We appreciate the collaboration of our investigators in Hong Kong.”
Share:
More News
“We believe TCEs have a powerful role to play in the future of immunotherapy to treat cancer. This collaboration with Gilead provides an opportunity to generate multiple differentiated candidates aimed at difficult-to-address solid tumors and to expand the potential impact of our science, while also advancing our own clinical oncology
“Patients with KRAS G12D-driven cancers deserve an effective, highly targeted therapy suitable for long-term treatment. Today’s first multi-tumor clinical dataset for VS-7375 demonstrates compelling and robust responses across KRAS G12D-mutated cancers, marking an important development milestone and reinforcing our conviction that VS-7375 has the potential to become both a best-in-class
“FDA acceptance of the UGN-103 NDA advances our vision for the next evolution of our portfolio and our continued commitment to transforming the treatment of recurrent LG-IR-NMIBC,” said Liz Barrett, President and CEO, UroGen. “Building on our experience with ZUSDURI (mitomycin) for intravesical solution, UGN-103 combines our proprietary RTGel® technology
“We are honored to be among the six recipients selected for funding through the FDA’s highly competitive Orphan Products Clinical Trials grants program,” said Juan Vera, MD, President and Chief Executive Officer of Marker Therapeutics. “This award represents meaningful independent recognition and external validation of the scientific rationale underlying our